The pemphigus vulgaris market reached a value of USD 282.0 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 565.3 Million by 2035, exhibiting a growth rate (CAGR) of 6.55% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 282.0 Million |
Market Forecast in 2035
|
USD 565.3 Million |
Market Growth Rate 2025-2035
|
6.55% |
The pemphigus vulgaris market has been comprehensively analyzed in IMARC's new report titled "Pemphigus Vulgaris Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Pemphigus vulgaris is a rare autoimmune disorder that affects the skin and mucous membranes, causing painful blistering and erosions. It can affect in various areas of the body, such as the mouth, throat, nose, genitals, abdomen, etc. The symptoms of the condition typically include the formation of fragile, fluid-filled blisters, leaving open sores that are painful and prone to infection. Various other indications are itching, burning, pain in affected areas, fever, fatigue, weight loss, etc. The ailment is diagnosed through a combination of clinical examination, skin biopsy, and blood tests. The healthcare professionals will typically begin by conducting a physical exam to assess the extent and severity of the blistering and erosions. They may also take a biopsy of the affected skin or mucous membrane to look for characteristic changes in the cells and tissues. Additionally, blood tests may be ordered to detect the presence of antibodies associated with pemphigus vulgaris.
The rising cases of immune system malfunction in which antibodies attack the proteins that hold skin cells together are primarily driving the pemphigus vulgaris market. Additionally, the escalating usage of various medications, such as nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, penicillamine, etc., which aid in triggering the onset of the ailment, is also propelling the market growth. Besides this, the widespread adoption of immunosuppressive agents in conjunction with corticosteroids to control the immune system and prevent the formation of new blisters is creating a positive outlook for the market. Moreover, the emerging popularity of plasmapheresis for treating severe cases of disease that do not respond to other treatments is acting as another significant growth-inducing factor. This procedure is used to remove autoantibodies and other immune system components that contribute to the development of the ailment. Furthermore, the rising usage of indirect immunofluorescence for diagnosing the disorder, which involves using fluorescent antibodies to detect the presence of autoantibodies, is also augmenting the market growth. Apart from this, the escalating demand for intravenous immunoglobulin therapy among patients with refractory disease or who are unable to tolerate systemic corticosteroids is expected to drive the pemphigus vulgaris market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the pemphigus vulgaris market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for pemphigus vulgaris and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pemphigus vulgaris market in any manner.
Rituxan (Rituximab), is a monoclonal antibody drug used to treat certain autoimmune illnesses, including pemphigus vulgaris. It is administered via gradual intravenous infusion (injection through an IV line). Rituximab is a chimeric monoclonal antibody that targets CD20, a surface antigen found on B lymphocytes. It depletes both normal and pathogenic B lymphocytes, while protecting plasma cells and hematopoietic stem cells that do not express the CD20 surface antigen.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current pemphigus vulgaris marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Rituxan (Rituximab) | Genentech, Inc. |
CABA-201 | Cabaletta Bio, Inc. |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Pemphigus Vulgaris: Current Treatment Scenario, Marketed Drugs and Emerging Therapies